Corline’s first Regenerative Medicine patent granted in the US
September 15th, 2011
Corline Systems AB has been granted Patent No. 7981873 by the US Intellectual Property Office.
“This is a break-through for Corline in the world’s largest and most influential market for Regenerative Medicine. Our technology holds potential to radically improve treatments for patients that really have no options today. IP protection is a crucial step to further commercialization”, comments CEO Henrik Nittmar.
The patent – titled ‘Novel use within Transplantation Surgery’ – covers methods for application and use of the company’s proprietary heparin coating technology for coating and protecting cells at transplantation, and specifically Islets of Langerhans for transplantation to diabetes Type-1 patients.
The life saving therapy of transplanting human donated insulin producing cells which are clustered together in what is referred to as Islets of Langerhans, has run into problems when translated from bench to clinic. One major area of challenge is to protect the transplanted cells from the immediate response of the receiving patient’s immune system, commonly referred to as the Innate Immune System, which leads to a massive cell loss during the first hour after transplantation. Corline has developed a unique heparin coating technology that can attenuate this reaction and save valuable donated cells from destruction. The Swedish Medical Products Agency has given its approval to start clinical trials for this promising technology.
“Supported by our recently granted funding from the EU commission, we are moving into clinical trials with our core technology in Europe. Next logical development step is to make a similar move for the huge US market, and the newly granted US patent is a necessary basis for future investment to realize such a plan. I am very pleased”, concludes CEO Henrik Nittmar.
